The three-year evolution of Germany’s Digital Therapeutics reimbursement...

Paper

Abstract

The 2019 German Digital Healthcare Act introduced the Digital Health Application program, known in German as 'Digitale Gesundheitsanwendungen' (DiGA). The program has established a pioneering model for integrating Digital Therapeutics (DTx) into a healthcare system with scalable and effective reimbursement strategies. To date, the continuous upward trend enabled by this framework has resulted in more than 374,000 DiGA prescriptions, increasingly cementing its role in the German healthcare system. This perspective provides a synthesis of the DiGA program's evolution since its inception three years ago, highlighting trends regarding prescriptions and pricing as well as criticisms and identified shortcomings. It further discusses forthcoming legislative amendments, including the anticipated integration of higher-risk medical devices, which have the potential to significantly transform the program. Despite encountering challenges related to effectiveness, evidence requirements, and integration within the healthcare system, the DiGA program continues to evolve and serves as a seminal example for the integration of DTx, offering valuable insights for healthcare systems globally.

Analysis

Paper intelligence

Summary

This paper reviews the evolution of Germany's DiGA program for digital therapeutics over three years, highlighting its successes, challenges, and future directions.

Key findings

The DiGA program has seen a continuous upward trend with over 374,000 prescriptions.
The program faces challenges related to effectiveness, evidence requirements, and healthcare system integration.
Forthcoming legislative amendments may integrate higher-risk medical devices, transforming the program.

Methods

Synthesis of the DiGA program's evolution.
Analysis of trends in prescriptions and pricing.
Review of criticisms and identified shortcomings.
Discussion of forthcoming legislative amendments.

Limitations

Effectiveness of DiGA.
Evidence requirements for DiGA.
Integration of DiGA within the healthcare system.

Applications

Integration of Digital Therapeutics into healthcare systems.
Reimbursement strategies for digital therapeutics.
Global insights for healthcare systems adopting DTx.

Confidence100%

Discovery

Related papers

2026Crossref0 citations

A Review on Software as Medical Devices (SaMD) as per USFDA

DROMA H. PATEL; Kalpana Patel; Sakshi Satya

Aug 26, 2026Journal of Regulatory Science

2026Crossref0 citations

QAI/ML-SaMD: A Hybrid Health–Technology Quantifiable Quality Metric for Artificial Intelligence/Machine Learning-Based Software as a Medical Device

Shouki A. Ebad

Aug 17, 2026Healthcare

2026Crossref0 citations

Gamified mental health: digital therapeutic alliance and mental well-being

Suhani Hirpara; Zidan Kachhi

May 1, 2026Mental Health and Digital Technologies

2026Crossref2 citations

Bridging the divide in digital therapeutics (DTx): Partnership strategies for broader representation across DTx development and deployment

Meelim Kim; Steven De La Torre; Uchechi Mitchell; Blanca Melendrez; Heather Cole-Lewis; Dana Lewis; Antwi Akom; Tessa Cruz; Bonnie Spring; Eric Hekler

Feb 20, 2026PLOS Digital Health

2026PubMed

Telemonitoring in the era of digital hypertension: beyond remote blood pressure monitoring.

Tomitani N; Kario K

Jan 1, 2026Hypertension research : official journal of the Japanese Society of Hypertension

2026PubMed

Model generalizability considerations in development and evaluation of SaMD.

Leng N; Lu Y; Fridlyand J; Tang T; Qi T; Wei Y; Sanchez RR; Simon N; Alexander G

Jan 1, 2026Journal of biopharmaceutical statistics

Source record

Publication metadata

Authors: Linea Schmidt; Marc Pawlitzki; Bernhard Y. Renard; Sven G. Meuth; Lars Masanneck
Published: May 24, 2024
Journal or venue: npj Digital Medicine
DOI: 10.1038/s41746-024-01137-1
Paper type: journal article
Source: Openalex

DOI OpenAlex